SUMMARY In mice breathing 5 percent oxygen, pretreatment with the optimal dose of 200 mg/kg of phenytoin increased survival time 123 percent This increase was somewhat less than that observed with certain barbiturates using the same model but significantly greater than that obsened with diazepam which is more effective than phenytoin in suppressing hypoxemlc convulsions in this model. In dogs maintained at an expired halotfaane concentration of either 0.87 percent or < 0.1 percent, phenytoin tended to decrease cerebral blood flow and had no effect on the cerebral metabolic rate for oxygen at 3 different doses. Assuming a similar effect in mice, the cerebral protection during hypoxemia observed with phenytoin cannot be explained by a reduction in metabolic rate, an increase in oxygen delivery, or by an anticonvulsant effect per se. In additional dog studies, pretreatment with phenytoin decreased the rate of potassium accumulation in cisteraal cerebrospinai fluid following 20 minutes of anoxia. We speculate that pbenytoin protection may be linked to this effect.
AMONG ITS MANY therapeutic uses, phenytoin has been reported to protect the brain during periods of reduced oxygen availability. Using cats or guinea pigs breathing only nitrogen as a model of cerebral anoxia, Naiman and Williams 1 showed that pretreatment with phenytoin prolonged survival as measured by the duration of respiratory activity. In a model of hypoxemia achieved by decompression, Hoff and Yahn 2 demonstrated that phenytoin pretreatment prolonged survival in mice and rats at any given hypoxic level and delayed the onset of clinical signs of hypoxia. Baldy-Moulinier 3 used a model of complete global ischemia produced by aortic clamping to show that survival time in cats was extended by phenytoin pretreatment. Finally, in a model of incomplete global ischemia for 15 minutes achieved via neck tourniquet in rabbits, Cullen et al. 4 found that administration of phenytoin immediately postischemia reduced cerebral histopathologic changes.
The present study was designed to examine the comparative cerebral protective effects of phenytoin using a mouse model which has already characterized the protective effects of various barbiturates, percent saline (controls).* The injected volume of phenytoin or saline ranged from 0.23 to 0.72 cc. Twenty minutes later one animal was placed in each of 5 interconnected airtight compartments, breathing room air supplied at 4 L/min for an additional 10 minutes of temperature equilibration. The compartments were kept in a versa-range test chamber (Blue-M Engineering Co., Division of Blue-M Electric Co., Blue Island, IL) which, at an ambient temperature of 35°C, maintained an intraperitoneal temperature of 36.9 ± 0.2°C. At the onset of each test period the room air gas supply was replaced by a mixture of nitrogen (N 2 ) 6-8 Vi L/min and 5 percent oxygen (O 2 ) in N a 15 L/min. After 60 seconds the N, flow was reduced to 0-0.5 L/min and after 120 seconds the O J / N J flow reduced to 3-4 L/min. Since Haldane analysis of our 5 percent O 2 sources showed variation between tanks (4.76-5.33 percent), gas flow rates were appropriately adjusted to produce a rapid fall of O t concentration in all chambers to 5-5.25 percent (in line Beckman O 3 analyzer) with maintenance of that concentration thereafter. Results from any chamber where the O, concentration exceeded the specified range were discarded. Survival time, defined as the time from initiation of hypoxic gas flow delivery to cessation of respiration, was recorded for each animal. In addition, behavioral observations were made at 30 minutes after drug injection as well as during hypoxia. Terminal hypoxemic seizure activity was graded either as present, reduced, or absent.
At least 15 animals were studied at each phenytoin dose simultaneously with controls. For each group of 5 animals, one to 2 control animals were sequentially rotated among compartments. Analysis of variance was done on the entire survival data. Where variance was confirmed, individual phenytoin doses were compared to controls with Student's /-test for unpaired 378 STROKE VOL 11, No 4, JULY-AUGUST 1980 samples. A contingency table was constructed for the hypoxemic seizure data and the chi-square value computed.
Canine Cerebral and Systemic Studies. Subjects were 12 unmedicated fasting mongrel dogs (weight 14 to 21 kg). Anesthesia was induced with halothane (1 percent) and nitrous oxide (60-70 percent) in oxygen. Succinylcholine, 30 mg as a bolus injection, followed by infusion of 100 mg/h facilitated endotracheal intubation and maintained relaxation. Ventilation was controlled with a Harvard pump and adjusted along with the inspired oxygen concentration to maintain serial blood gases (IL electrodes 37°C) at a Pao 2 near 150 mm Hg and a PacOi near 40 mm Hg.
A triple lumen catheter (Type 5F, child, 70 cm, Instrumentation Laboratory Inc., 113 Hartwell Avenue, Lexington, MA) was passed through the right internal jugular vein and its distal end placed in the pulmonary artery (PA), as verified by presence of the characteristic wave form. Cardiac output (Q) was calculated by a dye dilution technique* using a densitometer to measure the concentration of cardiogreen dye (sterile indocyanine green, Hynson, Westcott, and Donning, Inc., Baltimore, MD) in continuously sampled femoral artery blood after injection of the dye via the distal PA catheter port. A single lumen cannula was placed in the left femoral vein for fluid and drug administration. The left femoral artery was also cannulated for arterial blood gas sampling, buffer base (BB + ) determination, and both continuous systemic and mean arterial pressure (MAP) monitoring. With the animal in the prone position, the sagittal sinus was exposed and cannulated as previously described 10 for direct cerebral blood flow (CBF) measurement and cerebral venous blood gas sampling. Brain temperature was monitored by a parietal epidural thermistcr probe and maintained near 37.0°C with heat lamps. The EEG was monitored via bifrontal electrodes. The cerebral metabolic rate for oxygen (CMROa) was determined as the product of CBF and the arterial-cerebral venous (sagittal sinus) blood oxygen content difference. Blood oxygen contents were determined from measurements of oxygen tension (IL electrodes, 37°C), and oxygen saturation and hemoglobin (Hb) (IL 282 CO-oximeter) using 1.39 ml/g as the oxygen carrying capacity of Hb.
In four dogs the expired concentration of halothane (Beckman LB-2 Medical Gas Analyzer) was lowered to 0.87 percent and N 2 substituted for N 2 O in the inspired gas mixture. When stable baseline measurements had been established (at least 20 minutes later), an infusion of phenytoin in the commercial vehicle was begun and the response of the systemic and cerebral parameters was determined. At 0.87 percent halothane, a fall of mean arterial pressure (MAP) to near 50 torr was observed when phenytoin was infused, and in the remaining eight dogs the expired concentration of halothane was lowered to < 0.1 percent and N a O continued in the inspired gas mixture. Again, when stable baseline measurements had been established, a phenytoin infusion was begun and the response of the systemic and cerebral parameters was determined. In both groups phenytoin was infused at a fixed rate of 10 mg/min. A preceding pilot study showed that a more rapid infusion rate was associated with the development of a poorly tolerated metabolic acidosis. At 0.87 percent halothane, 2 dogs received 12.5 mg/kg phenytoin and 2 received 25 mg/kg. At < 0.1 percent halothane 3 dogs received a total phenytoin dose of 12.5 mg/kg, 3 received 25 mg/kg, and 2 received 50 mg/kg. In all groups, values for cerebral and systemic parameters were measured during the infusion of phenytoin 12.5 mg/kg at 5, 10, and 20 minutes (end infusion). During the infusion of 25 mg/kg, measurements were done at 5, 10, 20, and 40 minutes (end infusion). During the infusion of 50 mg/kg, measurements were done at 5, 10, 20, 40, 60, and 80 minutes (end infusion). After the administration of phenytoin had been completed, further measurements were made at 5 and 10 minutes, then every 15 to 20 minutes thereafter. In 4 animals, these values were measured to 180 minutes after end infusion but since no change was noted after 110 minutes, the remaining animals were observed only for that time interval. Serum phenytoin levels were drawn at end infusion and at 110 minutes.
The values for cerebral and systemic parameters during and following phenytoin administration were subjected to analysis of variance. Where variance was confirmed, values obtained during and following phenytoin were compared to those obtained during the control period using Student's r-test for paired data.
Canine CSF Electrolyte Studies. In 7 of our 12 animals, the rate of accumulation of CSF K + after both hypoxemia and circulatory arrest was determined. This group included 3 dogs from the < 0.1 percent halothane group and 4 from the 0.87 percent halothane group. Four animals had received 25 mg/kg phenytoin, 2 animals had received 12.5 mg/kg and one had received 50 mg/kg. At 110 minutes, these dogs were placed on N 2 (60-70 percent) in oxygen. After a stable baseline was achieved, the foramen magnum was cannulated with a No. 17 Touhy needle and 0.5 cc CSF withdrawn and centrifuged for sodium ([Na + ]c8p) and potassium ([K + ]cs F ) determination. The animals were then made hypoxemic by reducing the inspired oxygen content to 5 percent. When the end tidal oxygen concentration reached 5 percent (in line Beckman O 2 analyzer), 10 minutes were allowed to elapse before another CSF sample was drawn. Circulatory and cerebral arrest were then rapidly produced by reducing the inspired oxygen to 0 percent. Ten and 20 minutes after circulatory arrest, CSF samples were again taken. During this period, brain temperature was maintained at 37°C by heat lamps.
The changes in CSF electrolytes were compared to the changes observed in 14 dogs similarly prepared and monitored that did not receive phenytoin. Seven of these dogs were anesthetized with 1100 mg/kg yhydroxybutyrate (GHB) and N, (60-70 percent) in oxygen and 7 were anesthetized with N 2 O (60-70 percent) in oxygen. In the group which received GHB, CSF sampling was begun after 110 min of anesthesia, while in the N,O group sampling was begun after 120 min. Comparison of CSF electrolytes within groups was made using Student's Mest for paired samples.
Comparison of cerebral and systemic values, as well as CSF electrolytes, between groups was made using Student's Mest for unpaired samples.
Results

Mouse Protection Studies.
In the hypoxic mouse model, the mean survival times of the controls at each phenytoin dose were not significantly different and were therefore pooled. The resulting mean control value of 4.1 ±0.1 min did not differ from the mean control values reported in 2 previous studies that employed this model: 4.3 ± 0.2 min 11 and 3.8 ± 0.2 min. 8 Survival time was significantly prolonged in the groups pretreated with phenytoin 50, 100 and 200 mg/kg when compared to controls (table 1) . When these times were compared to survival time in a group of mice pretreated with diazepam (7.5 mg/kg), an effective anticonvulsant in this model, the groups which received phenytoin 100 or 200 mg/kg showed significantly prolonged survival time.
Phenytoin significantly altered hypoxic seizure activity (table 2). While doses of <. 100 mg/kg had little effect, doses of ;> 200 mg/kg attenuated but did not abolish seizure activity. With phenytoin ^ 100 mg/kg ataxia was noted. With 200 mg/kg spontaneous activity was reduced. With 300 mg/kg no spontaneous activity was observed, righting reflex was absent, respiratory rate was slow, and response to stimulus was reduced.
Canine Cerebral and Systemic Studies. While the halothane < 0.1 and 0.87 percent groups differed with respect to certain control values, the relative cerebral and systemic effects of phenytoin were similar (tables 3-4, fig.) In both groups these effects were not different among the 3 phenytoin infusion doses used (12.5, 25, and 50 mg/kg), and therefore these values were combined for each reported time interval (end of phenytoin infusion and 20, 60, and 110 minutes thereafter). CBF tended to be reduced (25-30 percent) during the infusion of phenytoin, then to recover in the first 20 minutes after the phenytoin infusion was con- eluded. Thereafter CBF was significantly reduced at 60-110 minutes. By comparison, there was no effect on CMRO, at any time. In the animals at < 0.1 percent halothane, EEG amplitude increased and frequency decreased with phenytoin infusion while no changes were seen at 0.87 percent halothane. The serum levels of phenytoin (table 5) correlated appropriately with the dose of phenytoin and the elapsed time between administration of phenytoin and blood sampling.
The major systemic effect was an approximate 1/3 reduction in cardiac output (0)-This decrease, which ranged from 15-50 percent during the study, was accompanied by a reduction in MAP -significant during the infusion period and for 20 to 60 minutes thereafter. The development of a moderate metabolic acidosis was also observed, while heart rate (not tabulated) did not change. (table 6) . After 10 minutes this increase was similar in all 3 groups, but after 20 minutes the increase was significantly less in the phenytoin treated animals (75 percent above control) than in the groups that did not receive phenytoin (GHB = 108 percent above control, NjO = 100 percent above control). [Na + ] C8F did not change in any of the groups with either hypoxia or anoxia.
DPH infusion
FIGURE. The mean values for certain cerebral and systemic parameters are plotted with respect to time following intravenous infusion of phenytoin (DPH). These values (representing all 12 dogs) are expressed as percent change from control, SEM'S are given in tables 3-4.
Discussion
Using the hypoxic mouse model a number of drugs (e.g. thiopental," pentobarbital," mephobarbital, 11 and diazepam 8 ) and conditions (e.g. hypothermia 8 and hypercarbia 7 ) have been shown to prolong survival. The cerebral protective effects of each of these drugs or conditions has been explained either by cerebral metabolic depression, 11 increased cerebral blood flow, 7 suppression of convulsions, 11 or by a combination of such effects. Based upon pur results these mechanisms do not conveniently explain the protective effects of phenytoin. Assuming no major species differences, phenytoin has no effect on CMRO 3 , tends to decrease CBF, and is less effective in suppressing terminal convulsions than diazepam.
The lack of a cerebral metabolic effect in the dog seems convincing for a number of reasons. There were no metabolic alterations observed at any of 3 different doses of phenytoin given at either anesthetic or subanesthetic concentrations of halothane. In the latter group, phenytoin did induce modest EEG changes but without a measurable metabolic component. Based upon the behavioral response of our mice to protective doses of phenytoin, it seems unlikely that major cerebral metabolic changes were produced in that species either. At the optimum protective dose (200 mg/kg), behavioral changes consisted only of mild ataxia with some decrease in spontaneous activity. At doses sufficient to suppress the righting reflex and response to stimuli (300 mg/kg) no protection was seen -presumably due to systemic toxic effects.
While we found no evidence of a CMRO 2 depressant effect with phenytoin, some evidence favoring a depressant effect has been reported. Broddle and Nelson 13 measured the rates of high energy phosphate and glucose utilization in mouse brain following decapitation. They reported that pretreatment with 200 mg/kg phenytoin reduced these utilization rates by 40 and 60 percent respectively while pretreatment with 20 mg/kg phenytoin produced no change. Using a rat brain synaptosome-mitrochondrial preparation Spector 14 reported that the addition of phenytoin to the incubation media reduced O, consumption 20 to 50 percent. The in vivo applicability of metabolic measurements obtained in these ways remains unknown; lacking further data it seems reasonable to conclude that phenytoin protection is likely not based upon cerebral metabolic depression.
The possibility that phenytoin might protect the brain by increasing CBF was not supported by our canine studies. During drug infusion CBF consistently fell simultaneous with reductions in both MAP and Q. After the infusion was completed, CBF initially returned toward control but then again decreased with time. The rate of decline in CBF (10-12 percent/h) we observed exceeds that previously reported for this model in a group of dogs similarly prepared and anesthetized with halothane <0.1 percent and N,O (60 to 70 percent) in O 2 ." Thus, while the decline in CBF may represent primarily an effect of time only on the preparation, a possible drug effect is suggested as well. Previous studies of phenytoin's effect on CBF have reported no uniform increase to above normal levels. In man, Kennedy et al. 18 reported that phenytoin returned the reduced CBF of epileptic children to normal levels. In cats subjected to a period of global ischemia, Baldy-Moulinier 3 reported a persistent decreased CBF unaltered by phenytoin. In rats, Kennedy et al. 1 7 used 14 C-antipyrine autoradiography and reported areas of both increased and decreased CBF following doses of phenytoin ranging from 10 to 100 mg/kg. All of the evidence supports the conclusion that phenytoin does not increase O t delivery to the brain and protection must be explained by some other mechanisms.
Although phenytoin is an effective anticonvulsant, it was only marginally effective in suppressing the terminal hypoxemic convulsions observed in the mouse model. A 50 mg/kg dose provided cerebral protection yet did not alter hypoxemic convulsions. The 100 and 200 mg/kg doses provided a greater degree of protection than diazepam (which also does not reduce CMRO, in suppressing hypoxemic convulsive activity. We therefore conclude that although suppression of convulsions might contribute, this cannot be the major mechanism by which phenytoin protects the hypoxemic mouse.
Another suggested mechanism for phenytoin protection relates to possible effects on ion flux across membranes. CSF K + may increase due to failure of active transport of K + from CSF to blood or from release of cerebral intracellular K + . Accumulation of CSF K + may aggravate the effects of reduced O 2 delivery and thereby decrease the brain's tolerance to hypoxemia/anoxia. 3 -1921 Phenytoin has been reported to reduce ion flux during both cerebral hypoxemia/anoxia 3> 22 and normoxia. 23 " 28 It may do so by enhancing the ATP dependent Na-K pump 2428 and/or by a direct membrane effect. 23 -"• 28 In any case, compared to our untreated anesthetized dogs, phenytoin treatment resulted in a slower rate of accumulation of cisternal [K + ] CSF during anoxia. Reduced CSF K + accumulation is not universally associated with all agents which provide cerebral protection. Pentobarbital 33 mg/kg, which provides equivalent cerebral protection to phenytoin 50 mg/kg in the hypoxic mouse, has no effect on CSF K + accumulation while hypothermia to 35°C, also equiprotective to phenytoin 50 mg/kg, minimally reduces CSF K + accumulation.*
The degree to which the sampled cisternal [K + ] C SF reflects either intracellular K + release or failure of outward transport depends on a variety of factorsthe rate of CSF production and absorption, the size of the compartment containing the CSF, and the percent of total CSF volume taken with each sample, to name a few. With the sampling technique we used, detection of any effect of phenytoin on either rate or magnitude of K + release would have been delayed and blunted. Thus we observed no [K + ] CSF changes during 10 minutes of hypoxia, and only after 20 minutes of anoxia were differences in the phenytoin treated animals apparent. In view of the lack of other obvious mechanisms to explain phenytoin protection, it seems reasonable to conclude that suppression of K + accumulation may be linked to the protective effect.
